Clinical Significance of Angiographically Detectable Neovascularity in Patients with Cardiac Myxoma
In a new publication from Cardiovascular Innovations and Applications ; DOI https://doi.org/10.15212/CVIA.2021.0025 , Xiaofan Peng, Yichao Xiao Yanan Guo and colleagues from Central South University, Changsha, Hunan, China consider the clinical significance of angiographically detectable neovascularity in patients with cardiac myxoma.
Myxomas are the most common primary cardiac tumors. Angiographically detectable neovascularity (ADN) of myxoma is increasingly being reported as a result of the use of coronary angiography (CAG) to detect coronary artery disease. However, the clinical significance of these findings is not fully understood.
The authors of this paper enrolled 59 patients with cardiac myxoma who also underwent CAG between January 2013 and October 2018. The clinical features, echocardiography measurements, pathological examination findings, CAG results, and outcomes during follow-up were compared between patients with ADN and patients without ADN.
The results demonstrated that CAG-detected ADN in patients with cardiac myxoma is associated with a borderline lower rate of major adverse cardiac and cerebrovascular events.
Citation information: Clinical Significance of Angiographically Detectable Neovascularity in Patients with Cardiac Myxoma, Xiaofan Peng, Yichao Xiao Yanan Guo et al., Cardiovasc. Innov. App ., 2021, https://doi.org/10.15212/CVIA.2021.0025
Keywords: Cardiac myxomas; coronary angiography; angiographically detectable neovascularity; major adverse cardiac and cerebrovascular events
CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications . Submissions may be made using ScholarOne Manuscripts . There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal ; or Facebook .
Cardiovascular Innovations and Applications